🔗 Share this article Users Discontinuing Slimming Medications Regain Weight Far More Rapidly Than Those on Conventional Diets Weight management often requires long-term strategies. Fresh analysis indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt traditional diet and exercise plans. Research printed in a leading medical journal points out that while obese people often shed a large proportion of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping. "Users purchasing such treatments need to be aware of the risk of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb. This pace of regain implies a return to original mass in about a year and a half. Analyzing Approaches The study, which reviewed 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills. Researchers emphasize that individuals who lose weight through diet and exercise typically experience a less rapid weight regain—perhaps 100 grams monthly—after stopping. The Reason for the Quick Regain Experts suggest the way of the drugs is key to understanding the heightened rebound. These medications mimic a natural hormone called GLP-1, which moderates hunger. "Sustained high doses of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist. "Stopping of this medication means hunger is unsuppressed, making binge eating much more probable." An Ongoing Condition? The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes. A number of clinicians argue that, given the high risk of relapse, the treatment might need to be long-term. This view is supported by drug manufacturers, who note that the findings "highlight the chronic nature of excess weight," similar to managing conditions like hypertension. User Testimonies Individuals who have come off the medication report a powerful return of appetite. "It felt as if a trigger activating and you become starving," recalled one woman. This challenge is exacerbated if patients have not developed sustainable dietary or behavioural modifications during treatment. Growing Interest Recent estimates show that a significant number of people in the UK have tried these injections in the past year, with desire being substantial. Adoption is higher among women than men. The 40s and 50s demographic shows the highest level of interest. Many access the medications through private healthcare rather than the NHS. In conclusion, researchers caution that while the jabs are powerful agents for weight loss, they are not a magic cure and long-term success hinges on ongoing behavioural support.
Weight management often requires long-term strategies. Fresh analysis indicates that patients who stop using popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt traditional diet and exercise plans. Research printed in a leading medical journal points out that while obese people often shed a large proportion of their body weight while using the jabs, the mass comes back at an average rate of 0.8 kg per month after stopping. "Users purchasing such treatments need to be aware of the risk of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb. This pace of regain implies a return to original mass in about a year and a half. Analyzing Approaches The study, which reviewed 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills. Researchers emphasize that individuals who lose weight through diet and exercise typically experience a less rapid weight regain—perhaps 100 grams monthly—after stopping. The Reason for the Quick Regain Experts suggest the way of the drugs is key to understanding the heightened rebound. These medications mimic a natural hormone called GLP-1, which moderates hunger. "Sustained high doses of the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist. "Stopping of this medication means hunger is unsuppressed, making binge eating much more probable." An Ongoing Condition? The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes. A number of clinicians argue that, given the high risk of relapse, the treatment might need to be long-term. This view is supported by drug manufacturers, who note that the findings "highlight the chronic nature of excess weight," similar to managing conditions like hypertension. User Testimonies Individuals who have come off the medication report a powerful return of appetite. "It felt as if a trigger activating and you become starving," recalled one woman. This challenge is exacerbated if patients have not developed sustainable dietary or behavioural modifications during treatment. Growing Interest Recent estimates show that a significant number of people in the UK have tried these injections in the past year, with desire being substantial. Adoption is higher among women than men. The 40s and 50s demographic shows the highest level of interest. Many access the medications through private healthcare rather than the NHS. In conclusion, researchers caution that while the jabs are powerful agents for weight loss, they are not a magic cure and long-term success hinges on ongoing behavioural support.